How much funding has Minerva Neurosciences raised?

Minerva Neurosciences has raised $220.0M in total funding, most recently a Venture Round.

Who are Minerva Neurosciences's investors?

Minerva Neurosciences's investors include Janus Henderson Investors.

When was Minerva Neurosciences founded?

Minerva Neurosciences was founded in 2007.

Where is Minerva Neurosciences headquartered?

Minerva Neurosciences is headquartered in Waltham, Massachusetts, United States.

What industry is Minerva Neurosciences in?

Minerva Neurosciences operates in Biotech, Healthcare.

How many employees does Minerva Neurosciences have?

Minerva Neurosciences has 11-50 employees.

Minerva Neurosciences

IPO

Public · Waltham, United States · Founded 2007 · $220.0M raised

Biotech

Healthcare

Headquarters: Waltham, Massachusetts
Employees: 11–50
Founded: 2007
Business Model: B2B
Website: minervaneurosciences.com

Total Funding: $220.0M
Last Round: $200.0M Venture RoundOct 2025
Rounds: 3
Type: Public

About

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Founded in 2007 and headquartered in Waltham, Massachusetts, the company has built its pipeline by identifying, acquiring, and in-licensing proprietary development-stage compounds with innovative mechanisms of action. Its lead product candidate, roluperidone, is being developed as a potential first-in-class treatment for negative symptoms in patients with schizophrenia. The company's strategy centers on leveraging randomized clinical trial data to advance candidates across multiple regulatory jurisdictions while selectively exploring collaborations with major pharmaceutical partners to maximize program value.

Summary

Minerva Neurosciences is a Biotech company based in Waltham, United States, founded in 2007. It has raised $220.0M in total across 3 rounds, most recently a $200.0M Venture Round round in Oct 2025. Investors include Janus Henderson Investors.